INTRODUCTION
Ulcerative colitis (UC) and Crohn's disease (CD) are chronic inflammatory bowel diseases (IBD) that are usually diagnosed in young ages. They seem to be the consequence of inappropriate inflammatory response in people with genetic predisposition (1) . Patients with IBD usually live a long life suffering from their disease (2, 3) . They could be affected by other chronic diseases independently or in relation to IBD. A chronic inflammatory process could involve many different organs apart from the primary site of inflammation (4) .
There are some studies in Iran showing the population and clinical characteristics of IBD to be the same as other developing countries. However, IBD's prevalence has increased during the last decades (5-7).
IBD is a multi organ disease. Extra intestinal presentations of IBD have been reported in several tissues including joints, skin, liver, and biliary system (8) .
However, pulmonary involvement is known to be rare. It
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Tanaffos 2012; 11 (3) : [23] [24] [25] [26] [27] was first reported in 1976 (9) . Pulmonary manifestations can be acute or sub-acute and could present as large or small airways, interstitial, and obstructive diseases (10) .There are few population-based studies investigating the pulmonary presentation of IBD. In most cases the subclinical pulmonary involvement has no or only a few symptoms (11, 12) . Moreover, confounding factors like cigarette smoking or previous history of lung diseases complicate the correlation between IBD and respiratory symptoms.
Environmental factors, genetics, microorganisms, and immunological conditions are known to interact with IBD's pathogenesis (13) . Similarities between small intestine and respiratory system along with their same embryonic origin are believed to cause comparable inflammatory changes in both organs (13, 14) . Pulmonary presentations are usually not related to the time of IBD diagnosis and in several cases have been reported in active or inactive episodes or even after colectomy (15) . Medications used for IBD, sulfa drugs and immunosuppressives cause interstitial lung diseases and infections (16) . Pulmonary presentations may cause bronchial hyper-responsiveness (BHR) (17) . It is reported that in more than 50% of UC cases there could be disturbances in respiratory function without any clinical or pathological findings (18) .
There are some studies that report a high incidence of BHR in IBD patients (12, 19) . Considering the positive results of methacholine challenge test, we investigated the BHR in UC patients in an Iranian population. Student's t test and Mann-Whitney test were utilized appropriately to compare data sets. P-value of <0.05 was considered statistically significant.
MATERIALS AND METHODS
RESULTS
Fifty-one UC patients were included in the study from October 2010 to October 2011. General characteristics of all patients are summarized in Table 1 . The average age was 43 ±14 (range 15 to 65) years. Number of males was higher.
A total of 13% of cases had comorbid diseases (3 uncontrolled hypertension and 4 uncontrolled diabetes mellitus). Eighteen percent had active disease during the study.
The average results of pulmonary function test (PFT) were within normal ranges (Table 2) Medications and cigarette smoking are two major factors affecting the lungs. In our study, smokers were excluded.
Most of our patients were in remission and; therefore, the majority was not on high doses of medication. However, there are studies that have reported higher incidence of BHR (19, 21) even as high as 48% (12) . All the aforementioned studies were carried out with small sample sizes and none of them had excluded smokers.
They also included patients with CD; positive outcome of methacholine test has been reported as high as 71% in CD (17) . could not find any significant difference between the incidence of BHR in IBD (13%) and the control group.
Kullmann et al. (24) reported an 8% incidence rate for BHR in UC. Our results are in concordance with theirs. They also showed that BHR is not associated with disease activity. Other studies confirm the independence of pulmonary presentation from time of diagnosis and disease severity (19, 24, 25) .
Interestingly, it is reported that sympathetic activity is higher in UC patients (26) . Therefore, in spite of the presence of any pulmonary pathology, methacholine challenge test may not be capable of revealing that.
Methacholine evaluates the cholinergic response. Increased sympathetic activity could lead to false negative results.
Nutrition is also found to be important in PFT results in IBD patients (4) . Patients in our study were mostly in remission phase and had a good nutritional condition that decreases the rate of abnormal PFT outcomes.
An interesting retrospective study on 2,192 patients with airway diseases for 10 years revealed that the prevalence of IBD was 4 times greater in them than in the normal population of the study (27) . Since this study was conducted in a tertiary health center the possibility of referral of patients with simultaneous complications could affect the results.
In general, the incidence of pulmonary presentation was reported to be greater in other studies compared to ours (17, 28) . Although such differences could be attributed to population variation, exclusion of smokers and patients with the history of allergic rhinitis is also important. The contradiction in results of various studies investigating pulmonary involvement secondary to IBD, and lack of any clear presentation of pathophysiologic pathways, raise a great concern about drawing any conclusion. The influence of any confounding factor and common risk factors should be evaluated in prospective cohort studies. Considering all contradictory data available on PFT and methacholine test results in UC, these tests should not be considered alone.
Pulmonary presentation should be interpreted in relation to medications used. Other diagnostic modalities, HRCT or bronchoscopy with lavage and biopsy should also be considered.
